Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745907 | 0.94 | L3MBTL1 (0.36) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL20745356 | 0.87 | L3MBTL1 (0.34) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL20745118 | 0.85 | SMN1; SMN2 (0.40) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL22262359 | 0.82 | CHRM2 (0.34) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL20745578 | 0.82 | CHRM2 (0.34) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL22262930 | 0.82 | CHRM2 (0.34) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL22262597 | 0.82 | CHRM2 (0.34) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL20745446 | 0.80 | SMN1; SMN2 (0.39) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL20745437 | 0.80 | SMN1; SMN2 (0.39) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL20745088 | 0.79 | SMN1; SMN2 (0.38) | L3MBTL1SMN1; SMN2KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3668504-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | L3MBTL1 76/4885SMN1; SMN2 609/4885KMT2A 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.